GRCL Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 113559 min ago

@ CNY10.28

Wydano: 14 vas. 2024 @ 22:48

Zwrot: -0.29%

Poprzedni sygnał: vas. 14 - 20:13

Poprzedni sygnał: Sprzedaż

Zwrot: -0.48 %

Live Chart Being Loaded With Signals

Commentary (21 vas. 2024 @ 23:00):

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China...

Stats
Dzisiejszy wolumen	6.37M
Średni wolumen	1.46M
Kapitalizacja rynkowa	989.87M
EPS	CNY0 ( 2024-03-11 )
Następna data zysków	( CNY0 ) 2024-05-13
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-10.57
ATR14	CNY0.215 (2.10%)

Wolumen Korelacja

Długi: 0.31 (neutral)

Krótki: 0.24 (neutral)

Signal:(68.183) Neutral

Gracell Biotechnologies Korelacja

10 Najbardziej pozytywne korelacje
NTRA	0.988
CRAI	0.983
RNA	0.976
HARP	0.976
PNTG	0.975
XLRN	0.974
ATRS	0.972
GXII	0.971
SFM	0.971
ARYD	0.97

10 Najbardziej negatywne korelacje
LPSN	-0.974
NARI	-0.971
BMBL	-0.97
VORB	-0.968
PEAR	-0.963
QNRX	-0.958
AMPH	-0.958
AKAN	-0.957
CNXC	-0.956
DMTK	-0.955

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gracell Biotechnologies Korelacja - Waluta/Towar

0.54
( weak )

0.89
( strong )

-0.03
( neutral )

0.35
( neutral )

0.23
( neutral )

-0.79
( moderate negative )

Gracell Biotechnologies Finanse

Annual	2022
Przychody:	CNY0
Zysk brutto:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2022
Przychody:	CNY0
Zysk brutto:	CNY0 (0.00 %)
EPS:	CNY-5.65

FY	2021
Przychody:	CNY366 000
Zysk brutto:	CNY0.00 (0.00 %)
EPS:	CNY-4.31

FY	2020
Przychody:	CNY0.00
Zysk brutto:	CNY0.00 (0.00 %)
EPS:	CNY-13.85

Financial Reports:

No articles found.

Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.